# Certara, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Certara, Inc.).

## Overview

Certara, Inc. builds biosimulation software and technology-enabled consulting services used in drug discovery and development. The company’s tools help biopharmaceutical teams apply model-informed drug development (MIDD) to predict outcomes, reduce development risk, and support regulatory submissions. Its platform is used across the life sciences value chain, from early research through clinical development and regulatory review. Certara also sells software to global drug regulators and provides project-based scientific services delivered by experienced drug-development specialists. The business is anchored in the adoption of quantitative modeling in life sciences rather than in traditional enterprise software workflows.

## Products & services

• Biosimulation software for drug discovery and development
• Cloud-based software subscriptions and maintenance
• Software licenses for validated scientific applications
• Technology-enabled consulting and MIDD project services
• Regulatory agency software used in drug review workflows

- **Software licenses** (30%) — Perpetual or term licenses for validated biosimulation applications delivered upfront.
- **Software subscriptions** (35%) — Cloud-based access and support for Certara software recognized ratably over the contract term.
- **Maintenance and support** (10%) — Ongoing support, updates, and maintenance tied to installed software and subscriptions.
- **Consulting and technology-enabled services** (25%) — Scientist-led project work that applies biosimulation and MIDD to customer programs.

- Biosimulation software for drug discovery and development
- Cloud-based software subscriptions and maintenance
- Software licenses for validated scientific applications
- Technology-enabled consulting and MIDD project services
- Regulatory agency software used in drug review workflows

## Customers

Certara sells primarily to biopharmaceutical and biotech companies that use its software and services to improve R&D decision-making and increase the probability of regulatory success. Its customer base also includes contract research organizations, academic and government institutions, and global regulators that license the software for review and scientific evaluation. The company serves customers across therapeutic areas such as oncology, hematology, diabetes, and rare diseases, which makes its platform relevant across many drug-development programs. It also has exposure to adjacent life sciences markets such as animal health, crop science, bio science, medical devices, and public sector organizations. Customer adoption is driven by the need to reduce development cost, accelerate timelines, and support safety and efficacy arguments with quantitative evidence.

- **Biopharmaceutical companies** (primary) — Buy biosimulation software and consulting to improve R&D productivity, support filings, and reduce development risk.
- **Biotech companies** (primary) — Use the platform for model-informed development with limited internal resources and high pipeline uncertainty.
- **Contract research organizations** (secondary) — Purchase software and services to execute modeling and simulation work on behalf of sponsor clients.
- **Regulators and government agencies** (secondary) — License software for scientific review, assessment, and decision support in drug regulation.
- **Academic and public sector institutions** (secondary) — Use the tools for research, training, and translational science applications.
- **Adjacent life sciences industries** (emerging) — Buy selected software and services for animal health, crop science, bio science, and medical devices.

- Large biopharma companies buying software and services to de-risk pipelines
- Biotech firms using MIDD tools to support smaller, faster development teams
- Contract research organizations needing modeling tools for client projects
- Academic and government institutions using the platform for research and evaluation
- Global regulators licensing software to assess submissions and review evidence
- Adjacent life sciences customers in animal health, crop science, and medical devices

## Geography

Certara operates globally and says its solutions have been used by customers in more than 70 countries. The company has direct exposure to major regulatory markets through software licenses at agencies such as the FDA, EMA, PMDA, China’s CDE, and the UK MHRA. Its commercial model depends on international adoption of biosimulation and MIDD, so regulatory acceptance in North America, Europe, and Asia is important to demand. The company also notes that it may partner with distributors in regions where it has less dedicated presence, indicating a mixed direct-and-partner go-to-market footprint. No country-level revenue split was disclosed in the provided excerpts, so the geographic mix below is based on operating footprint rather than authoritative revenue reporting.

- **United States** (45%) — Estimated from U.S. customer and regulatory exposure; no revenue geography table provided.
- **Europe** (25%) — Estimated from EMA/UK MHRA and broader European customer base.
- **Asia-Pacific** (20%) — Estimated from PMDA, China CDE, and broader international adoption.
- **Rest of World** (10%) — Residual estimate for other international markets.

- Global customer base across more than 70 countries
- Strong exposure to the United States through FDA-related use cases
- European presence through EMA and UK MHRA regulatory adoption
- Asia exposure through Japan PMDA and China CDE usage
- International expansion supported by direct sales and distributors
- No country-level revenue split disclosed in the excerpts

## Strategy

Certara’s strategy is to expand the breadth and depth of its biosimulation platform across the drug-development lifecycle. Management emphasizes continued investment in scientific talent, R&D, sales and marketing, and complementary acquisitions to broaden the solution set and extend international reach. The company is also focused on increasing customer retention and expansion through higher bookings and net retention, which matters because the model depends on recurring software usage and repeat project work. A key strategic objective is to deepen adoption of MIDD by regulators and academic institutions, since broader acceptance supports demand from biopharma customers. The company’s growth plan is tied to making its software and services more embedded in customer workflows so that switching costs and renewal rates remain high.

- **Broaden the platform with new software and services** (medium-term) — A wider product set increases wallet share and makes Certara more embedded in customer workflows.
- **Expand international commercial reach** (medium-term) — Growth depends on adoption across more geographies and regulatory systems.
- **Drive regulatory and scientific acceptance of MIDD** (long-term) — Regulatory support is a key demand driver for biosimulation in drug development.
- **Pursue acquisitions and complementary businesses** (medium-term) — Acquisitions can add capabilities, customers, and cross-sell opportunities.

- Expand the biosimulation platform across more stages of drug development
- Invest in scientific talent to strengthen domain credibility and services
- Grow software and services adoption in existing and new geographies
- Use acquisitions to add capabilities and broaden the product portfolio
- Increase customer retention and net retention through deeper workflow integration
- Support regulatory acceptance of MIDD to expand market demand

## Risks

Certara’s demand depends on continued acceptance of model-informed drug development by regulators, academic institutions, and biopharma customers; if adoption slows, software and consulting demand could weaken. The company is also exposed to customer concentration in the sense that a large share of revenue comes from a relatively small number of large biopharma clients, so consolidation or R&D budget pressure can reduce license counts and service volumes. Because the business relies on software platforms and cloud delivery, cyberattacks, outages, or data-security failures could disrupt operations and damage trust with regulated customers. International expansion and work with government agencies also create compliance exposure, including anti-bribery, privacy, and public-sector procurement rules. More generally, the company faces competitive pressure in a fragmented market where some customers may still use traditional, non-model-based development methods or alternative software tools.

- **Slow acceptance of model-informed biopharmaceutical development** [high] — Demand for Certara’s software and services depends on regulators and customers continuing to embrace biosimulation and MIDD.
- **Customer consolidation in biopharma** [high] — Mergers can reduce the number of licenses and users, and merged companies may negotiate lower prices.
- **Cybersecurity and service disruption** [high] — The company relies on software applications and IT systems that could be affected by cyberattacks, outages, or failures.
- **Compliance with anti-bribery and public-sector rules** [medium] — Sales to regulators and foreign government-related entities increase exposure to FCPA, Bribery Act, and procurement compliance.

- Regulatory or academic resistance to MIDD could slow adoption
- Biopharma consolidation can reduce user counts and license demand
- Cybersecurity incidents could disrupt software delivery and customer trust
- Dependence on large customers creates renewal and pricing pressure
- International operations increase compliance and anti-corruption risk
- Competitive fragmentation can pressure pricing and win rates

## Accounting

Certara’s revenue recognition is a key accounting area because the company sells a mix of upfront software licenses, ratable subscriptions, maintenance, and project-based consulting. License revenue is recognized upon delivery, while subscription revenue is recognized over one to three years, which can create timing differences between bookings and reported revenue. The company also reports seasonality, with revenue typically highest in the fourth quarter due to customer sales and renewal cycles, so quarterly comparisons can be uneven. Acquisition accounting matters because management separately identifies revenue related to acquisitions in its organic revenue bridge, which affects how investors interpret underlying growth. In addition, the company notes valuation allowance judgments and other estimates, so tax assets, goodwill/intangible assets, and contingent consideration can materially affect reported results if assumptions change.

- **Revenue recognition for licenses, subscriptions, maintenance, and services** — Important for quarterly comparability and backlog interpretation
- **Seasonality and renewal timing** — Affects quarterly run-rate analysis
- **Organic revenue and acquisition adjustments** — Important for assessing core operating momentum
- **Valuation allowance and tax estimates** — Can create volatility in reported earnings

- Upfront software license revenue versus ratable subscription revenue affects timing
- Deferred revenue builds when subscription fees are billed in advance
- Fourth-quarter seasonality can distort quarter-to-quarter comparisons
- Organic revenue excludes acquisition effects and can differ from GAAP revenue growth
- Valuation allowance and other estimates can affect tax and earnings presentation
- Acquisition-related accounting can affect comparability and reported margins

---

*Last updated: 2026-04-28T14:26:24.853230+00:00*